论文部分内容阅读
目的:探讨血CA 19-9水平升高程度对胰腺导管腺癌根治术病人预后的影响。方法:回顾性分析2003年1月至2014年12月于我院行胰腺导管腺癌R0切除术240例病人的临床资料及随访结果。将病人按术前CA 19-9升高程度的不同分为正常组(5.0~34.9 U/m L)、轻度升高组(35.0~99.9 U/m L)、中度升高组(100.0~599.9 U/m L)、重度升高组(≥600.0 U/m L)和阴性组(<5.0 U/m L),对各组病人进行Kaplan-Meier生存分析,比较各组病人的预后是否有显著性差异。结果:CA 19-9中度升高组病人的平均生存时间最短。对总胆红素<10 mg/d L的病人分组后,CA 19-9中度升高组病人的平均生存时间与其余各组间均存在显著性差异。结论:术前CA 19-9中度升高(100.0~599.9 U/m L)而非重度升高(≥600.0 U/m L)提示胰腺导管腺癌根治切除术后预后不佳。
Objective: To investigate the effect of elevated serum CA 19-9 on the prognosis of patients undergoing radical resection of pancreatic ductal adenocarcinoma. Methods: Clinical data and follow-up results of 240 patients with pancreatic ductal adenocarcinoma R0 resection in our hospital from January 2003 to December 2014 were retrospectively analyzed. Patients were divided into normal group (5.0 ~ 34.9 U / m L), mild increase group (35.0-99.9 U / m L) and moderate increase group (100.0 ~ 599.9 U / m L), severe increase (≥600.0 U / m L) and negative group (<5.0 U / m L). Kaplan-Meier survival analysis was performed on each group of patients to compare whether the prognosis of each group of patients There are significant differences. Results: The mean survival of patients with moderate elevation of CA 19-9 was the shortest. After grouping patients with total bilirubin <10 mg / d L, there was a significant difference between the mean survival time of patients with moderate elevation of CA 19-9 and the rest of the groups. Conclusions: Preoperative CA 19-9 moderate elevation (100.0-599.9 U / m L) rather than severe elevation (≥600.0 U / m L) suggests poor prognosis after radical resection of pancreatic ductal adenocarcinoma.